GlaxoSmithKline's CEO Andrew Witty says that overhauling the company's drug discovery operation was a "major upheaval" but is now showing results. According to Reuters, Witty also says that in the last 15 years, the drug industry floundered by basing the discovery process on combinatorial chemistry, genomics, and proteomics. "These were all supposed to transform productivity yet none of them did.